Alefacept Side Effects
Medically reviewed by Drugs.com. Last updated on Jul 26, 2022.
For the Consumer
Applies to alefacept: parenteral powder for injection
Side effects include:
For Healthcare Professionals
Applies to alefacept: intramuscular powder for injection, intravenous powder for injection
Immunologic side effects including dose-dependent reductions in circulating CD4+ and CD8+ T lymphocyte counts have been reported.[Ref]
Cardiovascular side effects including coronary artery disorder (<1%) and myocardial infarction (<1%) have been the adverse reactions which most commonly resulted in clinical intervention.[Ref]
The total percentage of alefacept-treated patients hospitalized for cardiovascular events was 1.2%.[Ref]
Twenty five of the 1,357 patients who received alefacept were diagnosed with a total of 35 treatment-emergent malignancies. Six cases were basal cell and seventeen cases were squamous cell cancers of the skin. Three cases of lymphoma have been reported; one was classified as non-Hodgkin's follicle-center cell lymphoma and two were classified as Hodgkin's disease.[Ref]
Oncologic side effects including malignancies have been reported. Postmarketing reports of malignancies including skin, solid organ, lymphomas and leukemias have also been received.[Ref]
Chills have been reported to occur predominantly with intravenous administration.[Ref]
General side effects including chills (6%), dizziness, headache, and accidental injury have been reported. Postmarketing reports of sepsis and opportunistic infections (viral, fungal, and bacterial) have been received.[Ref]
Local side effects including injection site pain and injection site inflammation have been reported.[Ref]
Respiratory side effects including pharyngitis and increased cough have been reported. Postmarketing reports of pharyngitis have also been received.[Ref]
Musculoskeletal side effects including myalgia have been reported.[Ref]
Hepatic side effects including postmarketing reports of asymptomatic transaminase elevation, fatty infiltration of the liver, hepatitis, and severe liver failure have been received.
Genitourinary side effects including postmarketing reports of urinary tract infection have been received.
More about alefacept
- Drug interactions
- Dosage information
- During pregnancy
- Reviews (1)
- Drug class: selective immunosuppressants
Related treatment guides
1. "Product Information. Amevive (alefacept)." Biogen (2003):
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.